Physician profile
Heather E Vaughn
NPI 1578983235
$4,791.29
in general payments reported to CMS, 2019-2025
22 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.40 · 2022: $17.15 · 2023: $111 · 2024: $1,829 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.39 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $956.12 | 2024-2025 | Tavneos, Krystexxa, Evenity |
| Ani Pharmaceuticals, INC. | $869.88 | 2024-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $712.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $534.29 | 2023-2025 | Benlysta, Menveo, Bexsero |
| Ucb, INC. | $375.70 | 2024-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $286.88 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.24 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $120.09 | 2024-2025 | |
| Lilly USA, LLC | $114.01 | 2021-2024 | Taltz |
| Novo Nordisk INC | $105.73 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $100.21 | 2024-2025 | Orencia |
| Tersera Therapeutics LLC | $97.72 | 2025 | Quzyttir |
| Genzyme Corporation | $94.06 | 2025 | |
| Shield Therapeutics INC | $56.35 | 2025 | |
| Janssen Biotech, INC. | $54.05 | 2024 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $37.01 | 2024 | |
| Tactile Systems Technology INC | $32.74 | 2023 | Entre Plus, Flexitouch Plus |
| Radius Health, INC. | $31.29 | 2025 | Tymlos |
| Dentsply Sirona INC | $19.58 | 2023 | Cavitron |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.40 | 2025 | Ofev |
| Aurinia Pharma U.S., INC. | $18.80 | 2025 | Lupkynis |
| Genentech USA, INC. | $14.56 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.